AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

 14,560.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 15,316.00
  • 52 Week Low: 10,022.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.98m
  • Volume: 0
  • Market Cap: £225,823m
  • RiskGrade: 123
  • Beta: 0.00

Latest ShareCast News

AstraZeneca receives positive high level results from Phase III I CAN trial

By Iain Gilbert

Date: Tuesday 21 Apr 2026

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that high‑level results from an interim analysis of its Phase III I CAN trial showed Ultomiris had met its primary endpoint, delivering a statistically significant and meaningful reduction in proteinuria in adults with IgA nephropathy at risk of disease progression.

AstraZeneca ShareCast News

AstraZeneca reports positive top-line data from ... 20-Apr-2026 ShareCast
AstraZeneca's COPD candidate succeeds in twin Ph... 27-Mar-2026 ShareCast
AstraZeneca's Calquence leukaemia treatment gets... 20-Feb-2026 ShareCast
Shore Capital lowers AstraZeneca to 'hold' 13-Feb-2026 ShareCast
Annual sales, profits jump at AstraZeneca 10-Feb-2026 ShareCast

AstraZeneca Regulatory News

Director/PDMR Shareholding 22-Dec-2025 11:00 RNS
Enhertu granted BTD for post-neoadjuvant early BC 22-Dec-2025 07:30 RNS
Update on LATIFY Phase III trial of ceralasertib 22-Dec-2025 07:00 RNS
Director/PDMR Shareholding 19-Dec-2025 11:00 RNS

AstraZeneca Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail
Some reasons why Pfizer won’t bid for AstraZenec... 19-Nov-2014 Guardian
Pfizer unlikely to try AstraZeneca takeover agai... 07-Nov-2014 Guardian

AstraZeneca Tips & Analysis

Questor :AstraZeneca 29-Apr-2014 Telegraph
Questor : AstraZeneca 24-Jan-2014 Telegraph
Questor:AstraZeneca 22-Dec-2011 Telegraph
Investment Column:AstraZeneca 28-Oct-2011 The Independent
Investment Column: AstraZeneca 23-Jun-2011 The Independent

AstraZeneca News Wires

MedImmune Announces Zook as President 13-Nov-2008 PR Newswire
Survey Shows Lung Cancer Patients Blamed for The... 12-Nov-2008 PR Newswire
CRESTOR Demonstrates Dramatic CV Risk Reduction ... 09-Nov-2008 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 14,560.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 15,316.00
52 Week Low 10,022.00
Volume 0
Shares Issued 1,550.98m
Market Cap £225,823m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Income
68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 13
Neutral 3
Sell 0
Strong Sell 1
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 19-Feb-26 07-Aug-25
Paid 23-Mar-26 08-Sep-25
Amount 217.00¢ 103.00¢

Trades for --2026

Time Volume / Share Price
0 @ 0.000p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page